Advertisement
Financing › Details
Mologen–SEVERAL: investment, 201809 capital increase €8.2m with 1.73m new shares at €4.7/share to existing + new investors
Period | 2018-09-03 � 2018-09-27 | |
Predecessor | Mologen–SEVERAL: investment, 201802–201803 capital increase €4.99m with 2.36m new shares at €2.12/share to existing + new investors | |
Money taker | Mologen AG | |
Group | Mologen (Group) | |
Money source | SEVERAL | |
Product | lefitolimod (MGN1703) | |
Product 2 | investment banking | |
Source | Mologen AG. (9/27/18). "Press Release: Mologen AG Completes Capital Increase with Gross Proceeds of around EUR8 Million [NOT FOR RELEASE IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, et al.]". Berlin. | |
Record changed: 2018-11-18 |
Advertisement
More documents for Mologen (Group)
- [1] Mologen AG. (12/3/19). "Press Release: Insolvency Filing [Not for publication or distribution in or into US, AU, CA or JP or any jurisdiction in which unlawful]". Berlin....
- [2] Mologen AG. (8/5/19). "Press Release: Mologen AG Announces Top Line Data of Pivotal IMPALA Study in Metastatic Colorectal Cancer. Primary Endpoint Not Met". Berlin....
- [3] Mologen AG. (3/27/19). "Press Release: Top Pharma Manager Stefan M. Manth, MD, to Become CEO of Mologen AG". Berlin....
- [4] Mologen AG. (3/18/19). "Press Release: Early Departure of CEO". Berlin....
- [5] Mologen AG. (1/17/19). "Press Release: Full Placement of Convertible Bond 2019/2027. Total Amount Issued: EUR2.7 Million, Maturity of 8 Years, Coupon of 6% p.a. [NOT FOR US, CA, JP, et al.]". Berlin....
- [6] Mologen AG. (11/16/18). "Press Release: Mologen AG to Retain Rights to Lefitolimod – Termination of Negotiations with Oncologie Inc. and Assessment of All Strategic Options in the Light of a Likely Read-out of the Pivotal Phase III IMPALA Trial in 2019"...
- [7] Mologen AG. (11/12/18). "Press Release: Lefitolimod – First Clinical Data in Combination with a Checkpoint Inhibitor and further Preclinical Results Presented at SITC 2018". Berlin....
- [8] Convert Pharmaceuticals S.A.. (11/8/18). "Press Release: Convert Pharmaceuticals Appoints Mariola Söhngen as New CEO"....
- [9] Mologen AG. (11/8/18). "Press Release: Implementation of Financing Measures and Publication of Study Results". Berlin....
- [10] Mologen AG. (9/27/18). "Press Release: Mologen AG Completes Capital Increase with Gross Proceeds of around EUR8 Million [NOT FOR RELEASE IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, et al.]". Berlin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top